Kintara Therapeutics, Inc.

0.20 USD
+0.02 (+9.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kintara Therapeutics, Inc. stock is up 42.86% since 30 days ago. The next earnings date is Sep 16, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 11 June’s closed higher than May.

About Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell Val-083 in China.